ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-21 EDT			5-day change	1st Jan Change
1.9 ^USD	-1.04%		-4.28%	-4.04%

05-09	Transcript : ProQR Therapeutics N.V. - Special Call
05-09	ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

ProQR Therapeutics N.V. Announces Stepping Down of Dinko Valerio as Chairperson

April 22, 2024

ProQR Therapeutics N.V. announced that having chaired the Board for the past 10 years, and in view of his tenure ending at the AGM 2026 Dinko Valerio, PhD, has elected to step down as chairperson and continue as a regular Board member.

Latest news about ProQR Therapeutics N.V.

Transcript : ProQR Therapeutics N.V. - Special Call	05-09
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer? RNA Editing Program Targeting NTCP for Cholestatic Diseases	05-08	CI
ProQR Therapeutics N.V. Announces Stepping Down of Dinko Valerio as Chairperson	04-22	CI
Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	03-14	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	01-05	CI
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	12-08	MT
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	12-06	CI
Raymond James Adjusts ProQR Therapeutics' Price Target to $4 From $5, Keeps Outperform Rating	11-08	MT
Chardan Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $2	11-08	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	11-06	MT
ProQR Therapeutics Says Sale of Ophthalmic Assets to Laboratoires Thea Terminated	23-09-27	MT
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V..	23-09-26	CI
Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating	23-09-18	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?135 million.	23-07-31	CI
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating	23-05-24	MT
ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member	23-05-17	CI
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating	23-05-17	MT
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating	23-03-30	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Transcript : ProQR Therapeutics N.V. - Special Call	23-03-29

Chart ProQR Therapeutics N.V.

Duration

Period

More charts

Company Profile

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leberâs congenital amaurosis (LCA).

Sector

Biotechnology & Medical Research

Calendar

10:30am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ProQR Therapeutics N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.9 USD

Average target price

4.1 USD

Spread / Average Target

+115.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROQR THERAPEUTICS N.V.	-4.04%	155M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.53%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs